The revised Federal Food, Drug, and Cosmetic Act (FD&C Act) now allows for drug approval without animal testing. 

This has led some to question the future of non-clinical CRO companies, which specialize in conducting animal trials. 

However, non-clinical trials are still essential for drug development, and they cannot be replaced by organ-on-a-chip, microchips, or organoids.

This brings up a very important role for companies like us.

 Since revision has the potential to significantly impact the bio and pharmaceutical industry, 

MEPSGEN was excited to learn more about it at BIX 2023. 

MEPSGEN's enthusiastic team exhibited the latest MEPS-X series products at BIX 2023, and we also shared souvenirs with dear visitors. 

It was a very fruitful and meaningful time to participate in this event. 

Bioindustry is already huge but with our audience’s great enthusiasm and keen interest, we were very excited to see how our bio-industry will shape our future and accelerate the progress during our session which took place on 14^th of July.

 YongTae Kim, the founding CEO of MEPSGEN, led the session as a Chair with the topic of “Emerging Advanced Alternative Drug Test Platforms: Microphysiological Systems and Organoids.” 

We are deeply grateful for your attendance and participation. 

Your presence made this event truly special.

Your encouragement has given us the momentum we need to move forward. 

We appreciate your support, and we hope you'll join us on our next journey.